Peter N. Leigh

Brighton, ENG BN19PX, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.

Journal: Brain : a journal of neurology
Published: December 15, 2025

Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy.

Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: November 24, 2025

Impaired dynein function preserves spinal interneuron survival and positioning in an ALS-like mouse model.

Impaired dynein function preserves spinal interneuron survival and positioning in an ALS-like mouse model.

Journal: PloS one
Published: October 15, 2025

Stratifying IL-2 therapy in ALS: integrating biomarkers - Authors' reply.

Stratifying IL-2 therapy in ALS: integrating biomarkers - Authors' reply.

Journal: Lancet (London, England)
Published: September 22, 2025

Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.

Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.

Journal: The Lancet. Neurology
Published: December 10, 2024

Intronic FGF14 GAA repeat expansions impact progression and survival in multiple system atrophy.

Intronic FGF14 GAA repeat expansions impact progression and survival in multiple system atrophy.

Journal: Brain : a journal of neurology
Published: November 20, 2024

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

Journal: Lancet (London, England)
Published: October 25, 2024

Investigating the impact of socioeconomic status on amyotrophic lateral sclerosis.

Investigating the impact of socioeconomic status on amyotrophic lateral sclerosis.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 01, 2024

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.

Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.

Journal: Annals of the New York Academy of Sciences
Published: May 21, 2024

Evaluation of cerebrospinal fluid alpha-synuclein seed amplification assay in PSP and CBS.

Evaluation of cerebrospinal fluid alpha-synuclein seed amplification assay in PSP and CBS.

Journal: medRxiv : the preprint server for health sciences
Published: March 26, 2024

Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.

Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.

Journal: Brain : a journal of neurology
Published: March 19, 2024

Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome.

Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: February 28, 2024
Showing 1-12 of 88

Last Updated: 09/26/2026